Bascom Palmer Eye Institute, University of Miami
Miami, Florida, 33136, United States
NCT Number: NCT05007288
The purpose of this research is to determine if restorative eye treatment (RET) and Inhance with trihex technology used before and after blepharoplasty can lead to better skin quality before undergoing blepharoplasty, and if these products will lead to less visible scarring and faster healing after blepharoplasty.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Miami, Florida, 33136, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
Time frame: Up to 1 month prior to blepharoplasty surgery
Assessed from eyelid tissue samples
Time frame: Up to 1 month prior to blepharoplasty surgery
Assessed from eyelid tissue samples
Time frame: Up to 2 weeks post blepharoplasty surgery
Bruising will be assessed on a 1-5 scale with the higher score indicating more bruising.
Time frame: Up to 2 weeks post blepharoplasty surgery
Swelling will be assessed on a 1 to 5 scale with the higher score indicating more swelling
University of Miami
Other
A Single Center Evaluation of Restorative Eye Treatment and Inhance With Trihex Technology Effects on the Aesthetic Outcomes When Used Pre and Post Upper Blepharoplasty
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04235803
Blepharoptosis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
San Francisco, California, United States
View Trial DetailsNCT06121141
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases
Surrey, British Columbia, Canada
View Trial DetailsNCT04585217
Blepharoptosis, Cicatrix
Boston, Massachusetts, United States
View Trial DetailsNCT02830776
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases
New Orleans, Louisiana, United States
View Trial Details